-$0.04 Earnings Per Share Expected for Antares Pharma Inc (ATRS) This Quarter

Brokerages expect Antares Pharma Inc (NASDAQ:ATRS) to post earnings per share of ($0.04) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Antares Pharma’s earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.04). Antares Pharma posted earnings per share of ($0.03) during the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The company is scheduled to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.13) to ($0.06). For the next fiscal year, analysts anticipate that the business will report earnings of $0.24 per share, with EPS estimates ranging from $0.00 to $0.60. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. The firm had revenue of $23.29 million for the quarter, compared to analyst estimates of $17.46 million.

ATRS has been the topic of a number of analyst reports. Cowen initiated coverage on shares of Antares Pharma in a research report on Monday, February 25th. They issued an “outperform” rating and a $1.99 price objective on the stock. BidaskClub lowered shares of Antares Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Raymond James lifted their price objective on shares of Antares Pharma from $5.25 to $5.65 and gave the company a “strong-buy” rating in a research report on Monday, March 4th. TheStreet upgraded shares of Antares Pharma from a “d” rating to a “c” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.50 price objective on shares of Antares Pharma in a research report on Monday, May 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Antares Pharma has a consensus rating of “Buy” and an average target price of $4.83.

NASDAQ:ATRS traded down $0.01 during midday trading on Thursday, reaching $2.85. The stock had a trading volume of 18,406 shares, compared to its average volume of 978,564. Antares Pharma has a 12-month low of $2.40 and a 12-month high of $3.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.28 and a quick ratio of 1.90. The firm has a market cap of $465.09 million, a price-to-earnings ratio of -71.50 and a beta of 1.03.

In other Antares Pharma news, Director Leonard S. Jacob sold 92,078 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $3.00, for a total transaction of $276,234.00. Following the sale, the director now directly owns 301,970 shares in the company, valued at approximately $905,910. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jacques Gonella sold 200,000 shares of the business’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $3.65, for a total transaction of $730,000.00. Following the sale, the director now owns 9,385,848 shares in the company, valued at $34,258,345.20. The disclosure for this sale can be found here. Insiders have sold a total of 322,078 shares of company stock worth $1,086,334 over the last 90 days. Insiders own 5.49% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ATRS. BlackRock Inc. boosted its position in shares of Antares Pharma by 1.3% during the 3rd quarter. BlackRock Inc. now owns 9,929,257 shares of the specialty pharmaceutical company’s stock worth $33,362,000 after purchasing an additional 123,932 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Antares Pharma by 112.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock worth $3,162,000 after purchasing an additional 497,523 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in shares of Antares Pharma by 53.3% during the 3rd quarter. MetLife Investment Advisors LLC now owns 109,970 shares of the specialty pharmaceutical company’s stock worth $369,000 after purchasing an additional 38,239 shares in the last quarter. Morgan Stanley boosted its position in shares of Antares Pharma by 17.3% during the 3rd quarter. Morgan Stanley now owns 760,870 shares of the specialty pharmaceutical company’s stock worth $2,557,000 after purchasing an additional 112,221 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,487,465 shares of the specialty pharmaceutical company’s stock worth $21,798,000 after buying an additional 84,181 shares during the last quarter. Institutional investors own 40.66% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: What is the NASDAQ?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.